Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020108661 - HETEROCYCLIC COMPOUND AS CDK-HDAC DOUBLE-CHANNEL INHIBITOR

Publication Number WO/2020/108661
Publication Date 04.06.2020
International Application No. PCT/CN2019/122503
International Filing Date 02.12.2019
IPC
C07D 401/14 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
14containing three or more hetero rings
C07D 403/04 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
403Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
02containing two hetero rings
04directly linked by a ring-member-to-ring- member bond
C07D 487/04 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
487Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
A61K 31/519 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
CPC
A61K 31/519
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07D 401/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
14containing three or more hetero rings
C07D 403/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
403Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
02containing two hetero rings
04directly linked by a ring-member-to-ring-member bond
C07D 487/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
487Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
Applicants
  • 杭州英创医药科技有限公司 HANGZHOU INNOGATE PHARMA CO., LTD. [CN]/[CN]
Inventors
  • 张汉承 ZHANG, Hancheng
  • 叶向阳 YE, Xiangyang
  • 程鑫 CHENG, Xin
Agents
  • 上海一平知识产权代理有限公司 XU & PARTNERS, LLC.
Priority Data
201811457309.830.11.2018CN
Publication Language Chinese (ZH)
Filing Language Chinese (ZH)
Designated States
Title
(EN) HETEROCYCLIC COMPOUND AS CDK-HDAC DOUBLE-CHANNEL INHIBITOR
(FR) COMPOSÉ HÉTÉROCYCLIQUE UTILISÉ EN TANT QU'INHIBITEUR DE CDK-HDAC À DOUBLE CANAL
(ZH) 作为CDK-HDAC双通路抑制剂的杂环化合物
Abstract
(EN)
Provided by the present invention is a compound as shown in formula (I), comprising possible enantiomers and diastereomers thereof, and pharmaceutically acceptable salts, hydrates or solvates thereof. Also provided by the present invention are pharmaceutical compositions of the described compounds, a preparation method therefor and a use thereof in the treatment of diseases and disorders (including cancer).
(FR)
La présente invention concerne un composé tel que représenté par la formule (I), comprenant des énantiomères et des diastéréomères possibles de celui-ci, ainsi que des sels, hydrates ou solvates pharmaceutiquement acceptables de celui-ci. La présente invention concerne également des compositions pharmaceutiques des composés selon l'invention, leur procédé de préparation et leur utilisation dans le traitement de maladies et de troubles (y compris le cancer).
(ZH)
本发明提供如下所示的式(I)的化合物,包括它们的可能的对映异构体和非对映异构体,及其药学上可接受的盐,水合物或溶剂合物。本发明还提供了这些化合物的药物组合物,其制备方法,以及它们在治疗疾病和病症(包括癌症)中的用途。
Latest bibliographic data on file with the International Bureau